MilliporeSigma, the life science business of Merck KGaA, will provide multiple Mobius 2000-liter single-use bioreactors to increase the biomanufacturing capacity of Avid Bioservices, a Tustin, California-based contract development and manufacturing organization and a wholly owned subsidiary of Peregrine Pharmaceuticals, a clinical-stage biopharmaceutical company also headquartered in Tustin. With the Mobius bioreactors, Avid intends to increase biomanufacturing capacity at its Myford clinical and commercial manufacturing facility in Orange County, California, where the new bioreactors will be installed in mid-2017.

To prepare for the integration of MilliporeSigma’s Mobius bioreactors, Avid has installed the appropriate systems at its 40,000-square-foot Myford facility, which was designed to accommodate a fully disposable biomanufacturing process for late Phase III clinical and commercial biologics production. The facility can operate multiple bioreactors simultaneously. A 2,000-liter pilot batch is planned for later in May.

MilliporeSigma’s Mobius stirred tank bioreactor portfolio includes bioreactor sizes ranging from 3 liters to 2000 liters.

Source: MilliporeSigma